Skip header and navigation

Refine By

35 records – page 1 of 4.

[A comparative evaluation of the efficacy of immunocorrection in children with bronchial asthma living in ecologically contrasted regions]

https://arctichealth.org/en/permalink/ahliterature15907
Source
Lik Sprava. 1995 Jul-Aug;(7-8):59-61
Publication Type
Article
Author
S V Trishina
V N Zorin
Iu F Babin
S V Trishin
A V Ruban
V V Ruban
V S Skorobatskii
Source
Lik Sprava. 1995 Jul-Aug;(7-8):59-61
Language
Russian
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage
Adolescent
Aerosols
Air Pollution - adverse effects
Asthma - drug therapy - immunology
Child
Child, Preschool
Comparative Study
Ecology
English Abstract
Humans
T-Lymphocytes - drug effects - immunology
Thymus Hormones - administration & dosage
Ukraine
Abstract
Overall 50 children suffering from infectious-allergic bronchial asthma who live in ecologically contrasting regions were examined. Those children residing in unfavourable, in terms of ecological conditions, regions demonstrated diminution of the peripheral blood T-lymphocytes together with a decrease in their functional activity as well as in the activity of interleukin 2. It is in this group of children that immunomodulating effect of thymalin is less apparent. It is suggested that the relevant immune correction in such cases might be achieved through repeated courses of treatment with immunomodulating agents and rehabilitation of patients in favourable ecological conditions together with prescribing of other immunostimulators of selective action in respect of the T-link of the immunity system.
PubMed ID
8846376 View in PubMed
Less detail

[An evaluation of the action of new nutritional compounds with a radioprotective use on the body's immune state]

https://arctichealth.org/en/permalink/ahliterature49239
Source
Fiziol Zh. 1998;44(1-2):77-80
Publication Type
Article
Date
1998
Author
I V Kononko
O I Vinars'ka
Author Affiliation
Ukrainian State Medical Centre of Environmental Health, Ministry of Public Health of Ukraine, Kiev.
Source
Fiziol Zh. 1998;44(1-2):77-80
Date
1998
Language
Ukrainian
Publication Type
Article
Keywords
Adjuvants, Immunologic - pharmacology
Animals
B-Lymphocytes - drug effects - immunology
English Abstract
Food, Fortified
Immunity, Cellular - drug effects
Immunity, Natural - drug effects
Radiation-Protective Agents - pharmacology
Rats
T-Lymphocytes - drug effects - immunology
Time Factors
Abstract
Examination of radiosafety effect of the new nutrition compositions were carried out in the experiments. The immunomodifying influence of this products were established. It is shown the possibility of their addition to the ration of population from the polluted territory.
PubMed ID
9619412 View in PubMed
Less detail

Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.

https://arctichealth.org/en/permalink/ahliterature256989
Source
Kidney Int. 2014 Feb;85(2):258-64
Publication Type
Article
Date
Feb-2014
Author
Philip F Halloran
Jeff P Reeve
Andre B Pereira
Luis G Hidalgo
Konrad S Famulski
Author Affiliation
1] ?Alberta Transplant Applied Genomics Centre, University of Alberta, 250 Heritage Medical Research Centre, Edmonton, Alberta, Canada [2] ?Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Source
Kidney Int. 2014 Feb;85(2):258-64
Date
Feb-2014
Language
English
Publication Type
Article
Keywords
Biopsy
Canada
Fibrosis
Gene Expression Regulation
Genetic Predisposition to Disease
Genome, Human
Graft Rejection - genetics - immunology - pathology - prevention & control
Graft Survival - drug effects
Humans
Immunity, Cellular - drug effects - genetics
Immunity, Humoral - drug effects - genetics
Immunosuppressive Agents - therapeutic use
Kidney - drug effects - immunology - pathology
Kidney Transplantation - adverse effects
Molecular Diagnostic Techniques
Phenotype
Predictive value of tests
Regeneration - drug effects - genetics
Risk assessment
Risk factors
T-Lymphocytes - drug effects - immunology
Transplantation Tolerance
Treatment Outcome
Abstract
Prospective studies of unselected indication biopsies from kidney transplants, combining conventional assessment with molecular analysis, have created a new understanding of transplant disease states and their outcomes. A large-scale Genome Canada grant permitted us to use conventional and molecular phenotypes to create a new disease classification. T cell-mediated rejection (TCMR), characterized histologically or molecularly, has little effect on outcomes. Antibody-mediated rejection (ABMR) manifests as microcirculation lesions and transcript changes reflecting endothelial injury, interferon-? effects, and natural killer cells. ABMR is frequently C4d negative and has been greatly underestimated by conventional criteria. Indeed, ABMR, triggered in some cases by non-adherence, is the major disease causing failure. Progressive dysfunction is usually attributable to specific diseases, and pure calcineurin inhibitor toxicity rarely explains failure. The importance of ABMR argues against immunosuppressive drug minimization and stands as a barrier to tolerance induction. Microarrays also defined the transcripts induced by acute kidney injury (AKI), which correlate with reduced function, whereas histologic changes of acute tubular injury do not. AKI transcripts are induced in kidneys with late dysfunction, and are better predictors of failure than fibrosis and inflammation. Thus progression reflects ongoing parenchymal injury, usually from identifiable diseases such as ABMR, not destructive fibrosis.
PubMed ID
23965521 View in PubMed
Less detail

Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse.

https://arctichealth.org/en/permalink/ahliterature123830
Source
Bone Marrow Transplant. 2013 Jan;48(1):105-14
Publication Type
Article
Date
Jan-2013
Author
M. Hoegh-Petersen
M A Amin
Y. Liu
A. Ugarte-Torres
T S Williamson
P J Podgorny
J A Russell
A. Grigg
D. Ritchie
J. Storek
Author Affiliation
Department of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 1N4. mhoeghpe@ucalgary.ca
Source
Bone Marrow Transplant. 2013 Jan;48(1):105-14
Date
Jan-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Alberta - epidemiology
Anemia, Aplastic - therapy
Antilymphocyte Serum - adverse effects - blood - metabolism - therapeutic use
B-Lymphocytes - drug effects - immunology - metabolism
Cohort Studies
Female
Follow-Up Studies
Graft vs Host Disease - epidemiology - immunology - physiopathology - prevention & control
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Immunosuppressive Agents - adverse effects - blood - metabolism - therapeutic use
Incidence
Leukemia - prevention & control - therapy
Male
Middle Aged
Myelodysplastic Syndromes - prevention & control - therapy
Opportunistic Infections - epidemiology - etiology - virology
Recurrence - prevention & control
Severity of Illness Index
T-Lymphocytes - drug effects - immunology - metabolism
Virus Diseases - epidemiology - etiology - virology
Young Adult
Abstract
Anti-thymocyte globulin (ATG) is polyclonal, containing Ab specificities capable of binding to various immune-cell subsets implicated in the pathogenesis of GVHD, including T cells, B cells, natural killer cells, monocytes/macrophages, neutrophils and DC. We wished to determine which ATG specificities are important for GVHD prevention. We measured day 7 serum levels of 23 ATG specificities in 120 hematopoietic cell transplant recipients whose myeloablative conditioning included 4.5?mg/kg ATG (thymoglobulin). High levels of ATG specificities capable of binding to T- and B-cell subsets were associated with a low likelihood of acute GVHD (aGVHD). High levels of these ATG specificities were associated with increased rates of viral but not bacterial or fungal infections. They were not associated with an increased risk of malignancy relapse; on the contrary, high levels of ATG specificities capable of binding to regulatory T cells and invariant NKT cells were associated with a low risk of relapse. In conclusion, high levels of ATG antibodies to Ag(s) expressed on T and B cells are associated with a low risk of aGVHD and a high risk of viral but not bacterial or fungal infections. These antibodies have neutral or beneficial effects on relapse.
PubMed ID
22659684 View in PubMed
Less detail

[Betaferon--first experience of application in treatment of multiple sclerosis in Russia].

https://arctichealth.org/en/permalink/ahliterature209709
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(12):24-7
Publication Type
Article
Date
1997
Author
I A Zavalishin
N N Iakhno
T D Zhuchenko
A S Niiazbekova
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(12):24-7
Date
1997
Language
Russian
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - therapeutic use
Adult
Disease Progression
Drug Administration Schedule
Drug Evaluation
Follow-Up Studies
Humans
Injections, Subcutaneous
Interferon-beta - administration & dosage - therapeutic use
Magnetic Resonance Imaging
Middle Aged
Multiple Sclerosis - diagnosis - immunology - therapy
Recurrence
Russia
Safety
T-Lymphocytes - drug effects - immunology
Treatment Outcome
Abstract
32 patients (21-55 years old) with multiple sclerosis (MS) were treated. Remittent form of the disease was observed in 24 patients, secondary progressive one--in 8 individuals; the degree of disability was characterised as scores 0-3 (the first group) and scores 5-6 (the second one) according to scale EDSS. Betaferon was administered subcutaneously in the dose of 8 MIU every other day during the period from several months to 1 year and more. Improvement of the state was observed in 5 patients with remittent form, stop of the development of disease (absence of either aggravations or signs of MS progression) was found in 26 cases (21 with remittent form, 4 with secondary progressive form). The conclusion was made: betaferon cannot cure but can stop progression of the disease. Indications and contraindications for betaferon therapy were established and recommendations were given concerning regimen of the treatment prophylaxis and therapy of side-effects.
PubMed ID
9591060 View in PubMed
Less detail

Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.

https://arctichealth.org/en/permalink/ahliterature265101
Source
Scand J Immunol. 2012 Feb;75(2):157-67
Publication Type
Article
Date
Feb-2012
Author
M. Donia
N. Junker
E. Ellebaek
M H Andersen
P T Straten
I M Svane
Source
Scand J Immunol. 2012 Feb;75(2):157-67
Date
Feb-2012
Language
English
Publication Type
Article
Keywords
Adoptive Transfer
Adult
Aged
CD8-Positive T-Lymphocytes - drug effects - immunology - pathology
Cell Aging
Cell Proliferation
Denmark
Female
Gene Expression
Humans
Immunophenotyping
Interferon-gamma - genetics - immunology
Interleukin-2 - pharmacology
Lymphocytes, Tumor-Infiltrating - drug effects - immunology - pathology
Lysosomal-Associated Membrane Protein 1 - genetics - immunology
Male
Melanoma - immunology - pathology - therapy
Middle Aged
Primary Cell Culture
Skin Neoplasms - immunology - pathology - therapy
Telomere - immunology
Telomere Homeostasis - drug effects - immunology
Translational Medical Research
Tumor Necrosis Factor-alpha - genetics - immunology
Abstract
Adoptive cell therapy (ACT) with ex vivo expanded tumour-infiltrating lymphocytes (TILs) in combination with IL-2 is an effective treatment for metastatic melanoma. Modified protocols of cell expansion may allow the treatment of most enrolled patients and improve the efficacy of adoptively transferred cells. The aims of this study were to establish and validate the novel 'Young TIL' method at our institution and perform a head-to-head comparison of clinical-grade products generated with this protocol opposed to the conventional 'Standard TIL', which we are currently using in a pilot ACT trial for patients with melanoma. Our results confirm that 'Young TILs' display an earlier differentiation state, with higher CD27 and lower CD56 expression. In addition, CD8(+) TILs expressing CD27 had longer telomeres compared with the CD27(-). A recently described subset of NK cells, endowed with a high expression of CD56 (CD56(bright)), was detected for the first time in both types of cultures but at a higher frequency on Young TILs. Young and Standard TILs' reactivity against autologous tumours was similar, with significant expression of TNF-a/IFN-?/CD107a by CD8(+) TILs detected in all cultures analysed. However, either slow expansion with high-dose IL-2 only or large numerical expansion with a rapid expansion protocol, which is required for current therapeutic protocols, significantly modified TIL phenotype by reducing the frequency of less differentiated, cancer-specific TILs. These studies further support the adoption of the Young TIL method in our current ACT trial and highlight the importance of continuous quality control of expansion protocols.
PubMed ID
21955245 View in PubMed
Less detail

Comparison of immune status and 1,2-dimethylhydrazine induced tumorigenesis in brown--Norway and Fischer rats. Emphasis on splenic and colonic lymphocyte function.

https://arctichealth.org/en/permalink/ahliterature26681
Source
Cancer Lett. 1985 Jan;25(3):311-23
Publication Type
Article
Date
Jan-1985
Author
M. Locniskar
K M Nauss
P. Kauffman
P M Newberne
Source
Cancer Lett. 1985 Jan;25(3):311-23
Date
Jan-1985
Language
English
Publication Type
Article
Keywords
1,2-Dimethylhydrazine
Animals
Colon - drug effects - immunology
Colonic Neoplasms - chemically induced - immunology
Comparative Study
Cytotoxicity Tests, Immunologic
Dimethylhydrazines - toxicity
Dose-Response Relationship, Drug
Killer Cells, Natural - drug effects - immunology
Male
Methylhydrazines - toxicity
Rats - immunology
Rats, Inbred F344 - immunology
Rats, Inbred Strains - immunology
Research Support, U.S. Gov't, P.H.S.
Spleen - drug effects - immunology
T-Lymphocytes - drug effects - immunology
Time Factors
Abstract
Sym 1,2-dimethylhydrazine (DMH)-induced colon tumorigenesis was studied in immunologically different strains of rat: the Brown--Norway which is known to be immunologically a low-responder and the Fischer a high-responder. Brown--Norway rats received a total dose of 75, 150 or 225 mg DMH/kg or vehicle and Fischer rats received 150 mg DMH/kg or vehicle over a 3-week period. Rats were killed 5 months after the final treatment. Lymphocytes were isolated from the spleen and colon from rats treated with 150 mg DMH/kg or vehicle. Natural killer (NK) cell activity and the autologous mixed lymphocyte response (AMLR) as well as colon tumor incidence were compared between the two strains. Splenic and colonic intraperithelial lymphocytes (IEL) from the Brown--Norway strain demonstrated low NK activity and reduced splenic T lymphocyte proliferation in response to autologous non-T lymphocytes. As well, colonic lamina propria lymphocyte (LPL) proliferation was low and Brown--Norway rats had a low incidence of DMH-induced colon neoplasms (7%). In comparison, the Fischer rats had more effective splenic and IEL NK killing, enhanced splenic AMLR, enhanced LPL proliferation and a higher incidence of colon tumors (20%).
PubMed ID
3871659 View in PubMed
Less detail

Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.

https://arctichealth.org/en/permalink/ahliterature124372
Source
Diabet Med. 2012 Oct;29(10):1272-8
Publication Type
Article
Date
Oct-2012
Author
S. Axelsson
M. Hjorth
J. Ludvigsson
R. Casas
Author Affiliation
Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. stina.axelsson@liu.se
Source
Diabet Med. 2012 Oct;29(10):1272-8
Date
Oct-2012
Language
English
Publication Type
Article
Keywords
Adolescent
Aluminum Hydroxide - pharmacology - therapeutic use
CD4-Positive T-Lymphocytes - drug effects - immunology
CD8-Positive T-Lymphocytes - drug effects - immunology
Child
Diabetes Mellitus, Type 1 - blood - drug therapy - immunology
Female
Flow Cytometry
Glutamate Decarboxylase - pharmacology - therapeutic use
Humans
Immunologic Memory
Lymphocyte Activation - drug effects
Male
Phenotype
Receptors, CCR4 - drug effects
Receptors, CCR5 - drug effects
Sweden
T-Lymphocytes, Cytotoxic - drug effects
Th1 Cells - drug effects
Abstract
The balance between T helper cell subsets is an important regulator of the immune system and is often examined after immune therapies. We aimed to study the immunomodulatory effect of glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) in children with Type 1 diabetes, focusing on chemokines and their receptors.
Blood samples were collected from 70 children with Type 1 diabetes included in a phase II clinical trial with GAD-alum. Expression of CC chemokine receptor 5 (CCR5) and CCR4 was analysed on CD4+ and CD8+ lymphocytes after in vitro stimulation with GAD(65) using flow cytometry, and secretion of the chemokines CCL2, CCL3 and CCL4 was detected in peripheral blood mononuclear cell supernatants with Luminex.
Expression of Th1-associated CCR5 was down-regulated following antigen challenge, together with an increased CCR4/CCR5 ratio and CCL2 secretion in GAD-alum-treated patients, but not in the placebo group.
Our results suggest that GAD-alum treatment has induced a favourable immune modulation associated with decreased Th1/Tc1 phenotypes upon antigen re-challenge, which may be of importance for regulating GAD(65) immunity.
PubMed ID
22587593 View in PubMed
Less detail

D-penicillamine-induced autoimmunity in the Brown Norway rat: role for both T and non-T splenocytes in adoptive transfer of tolerance.

https://arctichealth.org/en/permalink/ahliterature57392
Source
Chem Res Toxicol. 2004 Oct;17(10):1299-302
Publication Type
Article
Date
Oct-2004
Author
Béatrice Séguin
Mary Jane Masson
Jack Uetrecht
Author Affiliation
Faculties of Pharmacy and Medicine, University of Toronto, Ontario M5S 2S2, Canada.
Source
Chem Res Toxicol. 2004 Oct;17(10):1299-302
Date
Oct-2004
Language
English
Publication Type
Article
Keywords
Administration, Oral
Adoptive Transfer
Animals
Antigen-Presenting Cells - drug effects
Autoimmunity - drug effects - immunology
Cytokines - metabolism
Immune Tolerance
Lymphocyte Activation - drug effects
Penicillamine - pharmacology
Rats
Rats, Inbred BN
Research Support, Non-U.S. Gov't
Spleen - cytology
T-Lymphocytes - drug effects - immunology - transplantation
Time Factors
Abstract
The D-penicillamine autoimmune syndrome observed in Brown Norway (BN) rats is similar to an idiosyncratic reaction seen in some patients. We have previously shown that 2 weeks of low dose (5 mg/day) D-penicillamine pretreatment completely prevented all clinical signs of autoimmunity normally observed in 60-80% of rats treated with high dose (20 mg/day) D-penicillamine. We demonstrated that this tolerance is immune-mediated; tolerance to D-penicillamine is long lasting, we can adoptively transfer splenocytes from tolerant rats into slightly irradiated naive syngeneic recipients, and rats exposed to low dose D-penicillamine produce tolerogenic cytokines [Masson, M. J., and Uetrecht, J. P. (2004) Tolerance induced by low dose D-penicillamine in the brown norway rat model of drug-induced autoimmunity is immune-mediated. Chem. Res. Toxicol. 17, 82-94]. The aim of this study was to provide further understanding of the cells that are responsible for transferring tolerance and to assess the presence of regulatory T cells in the spleen of tolerant animals. We cotransferred T cells or splenocytes depleted of T cells from tolerant BN rats with splenocytes from naive BN rats into lightly irradiated syngeneic recipients. We found that neither tolerant splenocyte subpopulation could completely prevent clinical signs of autoimmunity. These results demonstrate that immune tolerance to D-penicillamine-induced autoimmunity may require both antigen presenting cells and T cells.
PubMed ID
15487889 View in PubMed
Less detail

EGF receptor activation during allergic sensitization affects IL-6-induced T-cell influx to airways in a rat model of asthma.

https://arctichealth.org/en/permalink/ahliterature97450
Source
Eur J Immunol. 2010 Jun;40(6):1590-602
Publication Type
Article
Date
Jun-2010
Author
Kimitake Tsuchiya
Taisuke Jo
Naoya Takeda
Saba Al Heialy
Sana Siddiqui
Karim Hamdy Shalaby
Paul-André Risse
Karim Maghni
James G Martin
Author Affiliation
Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada.
Source
Eur J Immunol. 2010 Jun;40(6):1590-602
Date
Jun-2010
Language
English
Publication Type
Article
Keywords
Allergens - immunology
Animals
Asthma - immunology - metabolism
Blotting, Western
Bronchoalveolar Lavage Fluid - cytology - immunology
Cell Separation
Chemotaxis, Leukocyte - drug effects - immunology
Cytokines - biosynthesis
Disease Models, Animal
Enzyme Inhibitors - pharmacology
Flow Cytometry
Interleukin-6 - immunology
Lung - drug effects - immunology
Ovalbumin - immunology
Rats
Rats, Inbred BN
Receptor, Epidermal Growth Factor - immunology - metabolism
Reverse Transcriptase Polymerase Chain Reaction
T-Lymphocytes - drug effects - immunology
Tyrphostins - pharmacology
Abstract
EGF receptor (EGFR) is involved in cell differentiation and proliferation in airways and may trigger cytokine production by T cells. We hypothesized that EGFR inhibition at the time of allergic sensitization may affect subsequent immune reactions. Brown Norway rats were sensitized with OVA, received the EGFR tyrosine kinase inhibitor, AG1478 from days 0 to 7 and OVA challenge on day 14. OVA-specific IgE in serum and cytokines and chemokines in BAL were measured 24 h after challenge. To evaluate effects on airway hyperresponsiveness (AHR), rats were sensitized, treated with AG1478, intranasally challenged, and then AHR was assessed. Furthermore chemotactic activity of BALF for CD4(+) T cells was examined. The eosinophils, neutrophils and lymphocytes in BAL were increased by OVA and only the lymphocytes were reduced by AG1478. OVA significantly enhanced IL-6 concentration in BAL, which was inhibited by AG1478. However AHR, OVA-specific IgE and IL-4 mRNA expression in CD4(+) T cells were not affected by AG1478. BALF from OVA-sensitized/challenged rats induced CD4(+) T-cell migration, which was inhibited by both AG1478 treatment in vivo and neutralization of IL-6 in vitro. EGFR activation during sensitization may affect the subsequent influx of CD4(+) T cells to airways, mainly mediated through IL-6.
PubMed ID
20373517 View in PubMed
Less detail

35 records – page 1 of 4.